Cancer stem cells: an old idea-a paradigm shift, Cancer Res, vol.66, pp.1883-1890, 2006. ,
Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy, J Clin Oncol, vol.26, 2008. ,
Tumour stem cells and drug resistance, Nat Rev Cancer, vol.5, pp.275-284, 2005. ,
ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome, Cell Stem Cell, vol.1, pp.555-567, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-01431968
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature, Cancer Res, vol.69, pp.1302-1313, 2009. ,
URL : https://hal.archives-ouvertes.fr/hal-01431954
Differential characteristics of two new tumorigenic cell lines of human breast carcinoma origin, Int J Cancer, vol.77, pp.415-423, 1998. ,
Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67, Pathobiology, vol.80, pp.219-227, 2013. ,
Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes, Mol Cell Proteomics, vol.7, pp.1420-1433, 2008. ,
Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis, J Clin Oncol, vol.26, pp.2839-2845, 2008. ,
The PARP superfamily, Bioessays, vol.26, pp.882-893, 2004. ,
Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis, Breast Cancer Res Treat, vol.127, pp.273-281, 2011. ,
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy, J Clin Oncol, vol.29, pp.2150-2157, 2011. ,
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, vol.434, pp.913-917, 2005. ,
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, vol.434, pp.917-921, 2005. ,
Inhibition of poly(ADPribose) polymerase in tumors from BRCA mutation carriers, N Engl J Med, vol.361, pp.123-134, 2009. ,
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial, The Lancet, vol.376, pp.235-244, 2010. ,
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study, Lancet Oncol, vol.12, pp.852-861, 2011. ,
A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC), J Clin Oncol, vol.29, 2011. ,
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, vol.444, pp.756-760, 2006. ,
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia, Cancer Res, vol.65, pp.8912-8919, 2005. ,
Mechanisms of Methotrexate Resistance in Osteosarcoma, Clinical Cancer Research, vol.5, pp.621-627, 1999. ,
ABC transporters, drug resistance, and cancer stem cells, J Mammary Gland Biol Neoplasia, vol.14, pp.3-9, 2009. ,
A pharmacodynamic study of the P-glycoprotein antagonist CBT-1 in combination with paclitaxel in solid tumors, Oncologist, vol.17, p.512, 2012. ,